Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥6,174 JPY
Change Today -30.00 / -0.48%
Volume 1.3M
As of 1:00 AM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for takeda pharmaceutical co ltd (4502)

Year over year, Takeda Pharmaceutical Company Limited has seen their bottom line shrink from a gain of ¥106.7B JPY to a loss of ¥145.8B JPY despite an increase in revenues from ¥1.7T JPY to ¥1.8T JPY. An increase in the percentage of sales devoted to SGA costs from 32.88% to 34.46% was a key component in the falling bottom line in the face of rising revenues.
View Income Statement In U.S. Dollar
Currency in
Millions of Japanese Yens
As of:Mar 31
Mar 31
Mar 31
Mar 31
4 Year
TOTAL REVENUES1,508,932.01,557,267.01,691,685.01,777,824.0
Cost of Goods Sold433,194.0447,628.0490,263.0520,990.0
GROSS PROFIT1,075,738.01,109,639.01,201,422.01,256,834.0
Selling General & Admin Expenses, Total810,711.0987,134.0556,210.0612,613.0
R&D Expenses----341,560.0382,096.0
Depreciation & Amortization, Total----143,202.0176,402.0
Other Operating Expenses----27,048.0249,451.0
OTHER OPERATING EXPENSES, TOTAL810,711.0987,134.01,068,020.01,420,562.0
OPERATING INCOME265,027.0122,505.0133,402.0-163,728.0
Interest Expense-1,883.0-3,323.0-4,888.0-5,796.0
Interest and Investment Income6,296.05,192.04,689.05,576.0
NET INTEREST EXPENSE4,413.01,869.0-199.0-220.0
Income (Loss) on Equity Investments302.0866.01,000.01,337.0
Currency Exchange Gains (Loss)-2,382.0613.0-11,750.0-1,143.0
Other Non-Operating Income (Expenses)3,245.0-12,685.0-13,941.0-19,005.0
EBT, EXCLUDING UNUSUAL ITEMS270,605.0113,168.0108,512.0-182,759.0
Gain (Loss) on Sale of Investments--53,071.039,658.07,238.0
Gain (Loss) on Sale of Assets17,596.04,026.06,577.032,815.0
Other Unusual Items, Total-35,723.0-40,558.04,103.0-2,731.0
Other Unusual Items-35,489.03,090.0----
EBT, INCLUDING UNUSUAL ITEMS252,478.0129,707.0158,850.0-145,437.0
Income Tax Expense125,207.0-3,880.049,292.0-2,403.0
Minority Interest in Earnings-3,109.0-2,343.0-2,900.0-2,741.0
Earnings from Continuing Operations127,271.0133,587.0109,558.0-143,034.0
NET INCOME124,162.0131,244.0106,658.0-145,775.0
NET INCOME TO COMMON INCLUDING EXTRA ITEMS124,162.0131,244.0106,658.0-145,775.0
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS124,162.0131,244.0106,658.0-145,775.0

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4502:JP ¥6,174.00 JPY -30.00

4502 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $45.42 USD +0.01
Baxter International Inc $37.68 USD -0.20
Becton Dickinson and Co $151.29 USD +1.17
Biogen Inc $293.21 USD +0.91
Merck KGaA €96.27 EUR +0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation 4502 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.6x
Price/Book 2.2x
Price/Cash Flow 202.8x
TEV/Sales 1.8x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact TAKEDA PHARMACEUTICAL CO LTD, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at